P0863 : “Real-life”-experience with second generation direct acting antiviral (DAA) treatment in HCV patients (n = 149) von Werner, C.R, Egetemeyr, D.P, Malek, N.P, Lauer, U.M, Berg, C.P

Volltext

P1172 “REAL-LIFE”-EXPERIENCE WITH PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV GENOTYPE 1 (G1) PATIENTS (N = 131): SVR 24 RESULTS von Werner, C.R, Franz, C, Egetemeyr, D.P, Malek, N.P, Lauer, U.M, Berg, C.P

Volltext

P902 TELAPREVIR-TRIPLE THERAPY OF RECURRENT HCV GENOTYPE 1 (G1) INFECTION AFTER LIVER TRANSPLANTATION (LTX): SVR 24 RESULTS von Werner, C.R, Egetemeyr, D.P, Nadalin, S, Königsrainer, A, Malek, N.P, Lauer, U.M, Berg, C.P

Volltext